Is it a class effect, or one drug's problem? Every drug in a class, compared on FDA adverse-event reports: how often each reaction is reported for the drug versus all other drugs, and versus its class-mates.
FAERS cases with the drug as primary or secondary suspect. Click a drug for its label gap, or its standouts to filter the grid.
What the class acts on (ChEMBL), with protein structures from RCSB PDB.
How to read this. Each cell is one drug and one reaction. Its shade is the PRR: how much more often the reaction appears in that drug's FAERS cases than in all other cases. Gray means it doesn't meet the signal rule. A ring marks a drug that stands out against its own class: in cases naming only that drug, the reaction is reported at least twice as often as in cases of its class-mates (lower 95% bound of the ROR above 2, at least 10 cases). Reports that name several drugs of the class count for nobody in that comparison.
Class effect: a signal for most members and nobody stands out. Stronger in some: a class effect where some members stand out. Drug-specific: members stand out and few others signal. Explained: the term reports lack of effect or the treated disease.
FAERS reports are voluntary and unverified. Drugs differ in time on market, market size, indications and publicity, which all change reporting, so this is a screen to decide what to look at, never a ranking of safety or an incidence rate. Not medical advice. Data: FDA FAERS, ChEMBL, RCSB PDB, NLM DailyMed.